Integrity testing is a critical operation, especially for sterilizing grade filters used in biopharmaceutical processing. When performed correctly, an integrity test is a fast, definitive, non-destructive way to assure filter retention performance. Fortunately, there are few ways a non-integral filter will pass the integrity test, eliminating the possibility a non-retentive filter is used undetected. Unfortunately, there are a lot of ways an integral filter can fail the integrity test, resulting in retests, lost time, productivity and potentially lost product.
In this webinar you will:
- Gain confidence in your integrity testing results
- Provide justification for retests
- Understand specific challenges and eliminate them to assure the integrity test can be performed correctly the first time
Watch the presentation of this webinar here: https://bit.ly/3tDy8Ei
Recent PDA/BioPhorum publications outline risks for PUPSIT in sterilizing filtration. This webinar will summarize the key points and best practices for implementing PUPSIT.
PDA and BioPhorum have partnered to form a task force whose goal was to provide the industry and regulators with scientific data and analysis on the potential risks and benefits of implementing PUPSIT to improve sterility assurance. This webinar will describe the data generated by the task force studies and discuss considerations and best practices when implementing PUPSIT.
In this webinar, you will learn:
• How changing industry perspectives help overcome regulatory concerns and may influence regulatory perspective
• How improved process understanding affects risk assessment
• How improved final fill assembly design simplifies PUPSIT
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceMerck Life Sciences
In this webinar, you will learn:
- how to measure filter performance and capacity,
- how to optimize filter virus removal capability,
- and avoid potential pit-falls
Detailed description:
This webinar will cover all aspects of parvovirus filtration best practices: process development/ optimization, pilot scale-up, and validation and explain the important connections between these activities. The rationale for the recommended best practices will be explained by discussing the underlying mechanisms that control filter performance.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
Selecting the right aseptic filter for your process can be complicated: today’s biomanufacturer has many filter choices each offering distinct benefits. Understanding the specific needs for individual operations, in terms of flux, capacity, bioburden reduction or sterilizing performance, gamma or thermal compatibility and single or multi-use will inform decisions that have implications for the life of the process. This webinar will provide general customer guidance and explain the benefits and disadvantages of different options to help guide customers to the most appropriate filter for their operation.
In this webinar, you will learn:
- How filter design impacts performance
- Important criteria for filter selection
- New choices and options to maximize productivity for biomanufacturers
Good Manufacturing PracticeFor LVP,SVP, ophthalmic veterinary medicine, bulk chemicals & invitro diagnostic
For Good business Practice
A control process gives reproducibility & product consistency with in known limits
Provides license to do business.
Watch the presentation of this webinar here: https://bit.ly/3tDy8Ei
Recent PDA/BioPhorum publications outline risks for PUPSIT in sterilizing filtration. This webinar will summarize the key points and best practices for implementing PUPSIT.
PDA and BioPhorum have partnered to form a task force whose goal was to provide the industry and regulators with scientific data and analysis on the potential risks and benefits of implementing PUPSIT to improve sterility assurance. This webinar will describe the data generated by the task force studies and discuss considerations and best practices when implementing PUPSIT.
In this webinar, you will learn:
• How changing industry perspectives help overcome regulatory concerns and may influence regulatory perspective
• How improved process understanding affects risk assessment
• How improved final fill assembly design simplifies PUPSIT
Parvovirus Filtration Best Practices - 25 Years of Hands-On ExperienceMerck Life Sciences
In this webinar, you will learn:
- how to measure filter performance and capacity,
- how to optimize filter virus removal capability,
- and avoid potential pit-falls
Detailed description:
This webinar will cover all aspects of parvovirus filtration best practices: process development/ optimization, pilot scale-up, and validation and explain the important connections between these activities. The rationale for the recommended best practices will be explained by discussing the underlying mechanisms that control filter performance.
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter ValidationMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3kk0Qs1
In this webinar, you will learn:
- About the GMP Annex 1 draft regulatory overview
- How to incorporate the integrity testing & PUPSIT in the filtration systems validation
- How to design a bacterial retention test in terms of organism selection and single vs multiple use validation
Detailed description:
In this webinar we will discuss the implications of the EU GMP Annex 1 draft on the filtration of medicinal products and how this impacts the validation studies.
Bacterial Retention Testing is a critical part of the manufacturing validation process and is required by all regulatory bodies worldwide. Using case studies, our experts will explain how the Annex 1 draft is incorporated into the filtration systems validation exercise, specifically for integrity testing & PUPSIT (Pre-Use Post Sterilization Integrity Testing), the selection and justification of the appropriate test organism, and validation implications of single versus multiple use.
Selecting the right aseptic filter for your process can be complicated: today’s biomanufacturer has many filter choices each offering distinct benefits. Understanding the specific needs for individual operations, in terms of flux, capacity, bioburden reduction or sterilizing performance, gamma or thermal compatibility and single or multi-use will inform decisions that have implications for the life of the process. This webinar will provide general customer guidance and explain the benefits and disadvantages of different options to help guide customers to the most appropriate filter for their operation.
In this webinar, you will learn:
- How filter design impacts performance
- Important criteria for filter selection
- New choices and options to maximize productivity for biomanufacturers
Good Manufacturing PracticeFor LVP,SVP, ophthalmic veterinary medicine, bulk chemicals & invitro diagnostic
For Good business Practice
A control process gives reproducibility & product consistency with in known limits
Provides license to do business.
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)Merck Life Sciences
This presentation explores best practices and case studies in aseptic processing, including how to implement and manage PUPSIT. You will learn:
• Integrity Testing – the background on IT itself, why it is important, and how it works
• Filtration setups and single-use technology
• The PUPSIT debate and how PUPSIT can be achieved with current technology, final filling, formulation, filtration
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/remotevisit
Normal Flow Filtration: Design and Scale UpMilliporeSigma
This presentation explores bioprocessing filtration best practices, including design and scale up methods. You will learn:
• What is filtration?
• Filter capacity and fouling models
• Filter sizing approaches
• Scale up considerations
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.emdmillipore.com/remotevisit
Selection, sizing, and operation of bioprocess filtration trains for optimal ...Merck Life Sciences
To increase filter lifetime and improve the economics of filtering bioprocess streams, a prefilter is often installed upstream of a final sterilizing-grade filter. However, determining the economic optimum prefilter and final filter configuration can be challenging. Numerous prefilter options are available, the prefilter to final filter area ratio must be determined, and operating conditions must be selected that will both satisfy the filtration requirements and provide for an economical process that minimizes the filtration system footprint.
One approach towards achieving an optimal filtration system design is to test the bioprocess fluid with several filter configuration combinations and at a range of operating conditions. However, this can be a daunting task and even impractical given the high cost and limited availability of valuable bioprocess fluids. A better approach is to run a limited filtration trial and use a mathematical model that can accurately predict the behavior of the prefilter and final filter under different conditions.
In this webinar we describe a filtration model and test methodology to rapidly and efficiently design an optimal dual-stage filtration process. The model and methodology were applied to Milligard® PES filters, a new class of autoclavable and gamma sterilizable PES membrane prefilters that are designed to protect microfiltration and nanofiltration final filters in bioprocess streams. We show how a model fit to the data from one set of filtration conditions can be used to predict filtration performance at other prefilter to final filter area ratios and operating conditions, and to determine the economic optimum filtration configuration.
In this webinar, you will learn:
- How filters for microfiltration of biological fluids work.
- The effect of operating conditions on filtration performance.
- How to design an optimal series filtration (prefilter and final filter) process.
Find your filter. What’s best for your process? MilliporeSigma
Selecting the right aseptic filter for your process can be complicated: today’s biomanufacturer has many filter choices each offering distinct benefits. Understanding the specific needs for individual operations, in terms of flux, capacity, bioburden reduction or sterilizing performance, gamma or thermal compatibility and single or multi-use will inform decisions that have implications for the life of the process. This webinar will provide general customer guidance and explain the benefits and disadvantages of different options to help guide customers to the most appropriate filter for their operation.
In this webinar, you will learn:
- How filter design impacts performance
- Important criteria for filter selection
- New choices and options to maximize productivity for biomanufacturers
This presentation provides an introduction to tangential flow filtration and reviews the following:
- TFF process basics and terminology
- TFF membrane technology
- TFF hardware, devices and systems
- Growing applications and the future
To learn more about this topic or collaborate with our technical experts, schedule an in-person or remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/mlab
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)MilliporeSigma
This presentation explores best practices and case studies in aseptic processing, including how to implement and manage PUPSIT. You will learn:
• Integrity Testing – the background on IT itself, why it is important, and how it works
• Filtration setups and single-use technology
• The PUPSIT debate and how PUPSIT can be achieved with current technology, final filling, formulation, filtration
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.emdmillipore.com/remotevisit
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...Merck Life Sciences
View the recording here: https://bit.ly/2M6cTYD
Abstract:
Diafiltration is a critical unit operation in the downstream purification train for nearly all monoclonal antibodies and other therapeutic biomolecules, with a particular application being the final formulation step. It provides a cost-effective, efficient, and robust method for achieving > 3 logs of buffer exchange. As the biomanufacturing industry strives for more efficient and cost-conscious processes and facilities by adapting templates to be more flexible, handle larger batch sizes, require lower plant footprint, and run in an integrated or continuous mode, diafiltration has been one of the last unit operations to change. Updated technologies for chromatography, clarification, and concentration have been developed in recent years, offering significant improvements over their existing batch processing equivalents. However, it has been challenging to develop a similar intensified and continuous technology for diafiltration that exceeds established expectations around unit operation productivity while maintaining a process that is easily implementable and suitable for GMP manufacturing.
Our approach to intensified, continuous diafiltration bases the process design on membrane utilization, as opposed to flux and process time typically used for batch designs. The result is a flexible solution that offers 6-8-fold decrease in membrane area, up to 3-fold reduction in pump passes and a substantial footprint reduction. Buffer usage, extent of buffer exchange, and product yield are equivalent to a traditional constant-volume diafiltration process. The process development approach, system components, and process control rely on well-established methods and technologies, reducing risk during scaleup and manufacturing implementation.
In this webinar, you will learn:
- A new process design for continuous diafiltration and its operational robustness over a 24-hour run
- Benefits of implementing this version of intensified or continuous diafiltration in your process train
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...Merck Life Sciences
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
Single-Use Tangential Flow Filtration for Closed ProcessingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b7vD60
Closed processing involves use of physical barriers to separate processing fluid from the external environment. This approach reduces capital expenditures and clean room classification while accelerating time to market. This webinar will present a TFF process run in a closed mode.
Closed processing with single-use technologies is a critical enabler for efficient and robust manufacturing for novel modalities as well as continuous biomanufacturing processing. It can also reduce the dependence on classified clean rooms for traditional modalities. This approach helps to mitigate the risk of contamination by adventitious agents while enhancing operator safety.
In this presentation, we discuss the implementation of closed processing for downstream applications and present the design and performance testing of a single use manufacturing-scale tangential flow filtration system to be able to operate in both functionally and fully closed mode.
In this webinar, you will learn:
• The context of closed processing
• Differences between closed and functionally closed processing
• The drivers for adoption
• Its practical implementation to a TFF step
Aseptic / sterile- “ A state of control attained by using an aseptic work area and performing activities in a manner that precludes microbiological contamination of the exposed sterile product”
This presentation explores bioprocessing filtration best practices, including design and scale up methods. You will learn:
• What is filtration?
• Filter capacity and fouling models
• Filter sizing approaches
• Scale up considerations
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/remotevisit
This presentation covers the manufacture and testing of all sterile drug products, including drugs that are sterilized by filtration or other means and aseptically processed, and drug products that are terminally sterilized. The type of products covered include sterile bulk drugs, ophthalmic drugs, otic dosage forms, small volume parenteral (SVS) products for small molecule and licensed biological
therapeutic drug products, large volume parenteral (LVP) products, and any other drug products required to be sterile or labeled as sterile. Center for Biologics Evaluation and Research (CBER) regulated products and veterinary drug products are excluded from coverage under this program.
The guidance information is tailored to sterile manufacturing operations and should be used in conjunction with the Compliance Program for Drug Manufacturing Inspections (CP 7356.002).
Single-Pass Tangential Flow Filtration (SPTFF) Theory and PracticeMerck Life Sciences
This data-driven presentation explores the theoretical and practical implications of single-pass tangential flow filtration in bioprocessing and will address the following:
• What is single-pass TFF and how does it work?
• How does SPTFF improve process economics?
• How can single-use technology be utilized for speed and safety?
To learn more about this topic or collaborate with our technical experts, schedule an in-person or remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/mlab
Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
Experienced Quality Professional with a demonstrated history of working in the Top leading National pharmaceutical industries (Platinum, Bosch, Getz & Nabiqasim Pharma) of pakistan. Part of WHO & PIC/S Team.
Skilled in various function of Quality Assurance, Quality Management Sysytem,Validation & Qualification as described below.
1-Deviation Management System.
2-Change Control Management System.
3-Corrective & Preventive Action(CAPA).
4-Root Cause Analysis(Investigation).
5-Self Inspection (Level-I), GMP Inspection (Level-II), Internal Audit (Level-III).
6-Quality Risk Management System.
7-Market Complaint (Product Quality Defect).
8-Product Recall (Mock Recall).
9-Product Quality Review(APQR).
10-Management Review.
11-Supplier Qualification
12-ISO (9001,14001,45001 & 17025)
13-Validation Master Plan
14-Process Validation
15-Area & Equipment Qualification
16-Cleaning Validation
17-Calibration & Verification
18-Analytical Method Validation
Batch Manufacturing Record Auditing and Sop writing along with effective training sessions reagrding GMP.GDP.GLP & GSP.
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...Merck Life Sciences
This presentation provides an introduction to tangential flow filtration applications for AAV and lentivirus and will review:
• Basics of tangential flow filtration (TFF)
• TFF AAV and lentivirus process overview
• Operating parameters optimization: flux-controlled microfiltration
• Scale up considerations
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/remotevisit
Bioburden control: Strategies to address bioburden control in downstream proc...Merck Life Sciences
Biotherapeutic manufacturing processes are at greater risk of contamination than classic small molecule processes and therefore require different control strategies. Understanding the source, options for control, and potential impact of bioburden throughout downstream biopharmaceutical processes is beneficial to process developers, production operators and pharmaceutical microbiologists. Process designs that reduce the risks of bioburden contamination will decrease process related failures and the resulting painful, time-consuming investigations.
In this webinar, you will learn:
• Biotherapeutic manufacturing processes are at greater risk of contamination than classic small molecule processes and therefore require different control strategies.
• Understanding the source, options for control, and potential impact of bioburden throughout downstream biopharmaceutical processes is beneficial to process developers, production operators and pharmaceutical microbiologists.
• Process designs that reduce the risks of bioburden contamination will decrease process related failures and the resulting painful, time-consuming investigations.
Register for our webinar here: https://bit.ly/3c4q9rr
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...Merck Life Sciences
The successful adoption of single-use technologies in a biopharmaceutical process largely relies on confidently selecting the right components for use in the fluid path of a product, within a specific process. An important step in choosing such components requires generating an extractables profile, which can be done by carefully selecting the solvent streams and extraction conditions to model the product and process steps complemented with the right analytical strategy.
In this webinar, you will learn:
● An approach to adopt the BioPhorum Operations Group (BPOG) extractables protocol as a baseline testing strategy.
● How to apply extractables data to a specific process followed by a systematic, risk-based safety assessment approach used for comparing known safety concern thresholds.
● The important stages in the risk assessment process as demonstrated by case studies from typical drug manufacturing processes where single-use components were used.
Discover solutions for all phases of product development for genetox assessment from in silico analysis, screening, mode of action assessment, or GLP regulatory required assays. Our BioReliance® Genetic Toxicology Services director will share specifics and rationale for each assay category.
In this webinar you will:
- Learn the required regulatory assays
- Understand why each assay is used and how to employ different assay designs
- Learn different assays and techniques to screen potential compounds and understand mechanism and mode of action
Presented by Rohan Kulkarni, Ph.D., ERT, Director Toxicology, Study Management on February 9, 2017
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)Merck Life Sciences
This presentation explores best practices and case studies in aseptic processing, including how to implement and manage PUPSIT. You will learn:
• Integrity Testing – the background on IT itself, why it is important, and how it works
• Filtration setups and single-use technology
• The PUPSIT debate and how PUPSIT can be achieved with current technology, final filling, formulation, filtration
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/remotevisit
Normal Flow Filtration: Design and Scale UpMilliporeSigma
This presentation explores bioprocessing filtration best practices, including design and scale up methods. You will learn:
• What is filtration?
• Filter capacity and fouling models
• Filter sizing approaches
• Scale up considerations
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.emdmillipore.com/remotevisit
Selection, sizing, and operation of bioprocess filtration trains for optimal ...Merck Life Sciences
To increase filter lifetime and improve the economics of filtering bioprocess streams, a prefilter is often installed upstream of a final sterilizing-grade filter. However, determining the economic optimum prefilter and final filter configuration can be challenging. Numerous prefilter options are available, the prefilter to final filter area ratio must be determined, and operating conditions must be selected that will both satisfy the filtration requirements and provide for an economical process that minimizes the filtration system footprint.
One approach towards achieving an optimal filtration system design is to test the bioprocess fluid with several filter configuration combinations and at a range of operating conditions. However, this can be a daunting task and even impractical given the high cost and limited availability of valuable bioprocess fluids. A better approach is to run a limited filtration trial and use a mathematical model that can accurately predict the behavior of the prefilter and final filter under different conditions.
In this webinar we describe a filtration model and test methodology to rapidly and efficiently design an optimal dual-stage filtration process. The model and methodology were applied to Milligard® PES filters, a new class of autoclavable and gamma sterilizable PES membrane prefilters that are designed to protect microfiltration and nanofiltration final filters in bioprocess streams. We show how a model fit to the data from one set of filtration conditions can be used to predict filtration performance at other prefilter to final filter area ratios and operating conditions, and to determine the economic optimum filtration configuration.
In this webinar, you will learn:
- How filters for microfiltration of biological fluids work.
- The effect of operating conditions on filtration performance.
- How to design an optimal series filtration (prefilter and final filter) process.
Find your filter. What’s best for your process? MilliporeSigma
Selecting the right aseptic filter for your process can be complicated: today’s biomanufacturer has many filter choices each offering distinct benefits. Understanding the specific needs for individual operations, in terms of flux, capacity, bioburden reduction or sterilizing performance, gamma or thermal compatibility and single or multi-use will inform decisions that have implications for the life of the process. This webinar will provide general customer guidance and explain the benefits and disadvantages of different options to help guide customers to the most appropriate filter for their operation.
In this webinar, you will learn:
- How filter design impacts performance
- Important criteria for filter selection
- New choices and options to maximize productivity for biomanufacturers
This presentation provides an introduction to tangential flow filtration and reviews the following:
- TFF process basics and terminology
- TFF membrane technology
- TFF hardware, devices and systems
- Growing applications and the future
To learn more about this topic or collaborate with our technical experts, schedule an in-person or remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/mlab
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)MilliporeSigma
This presentation explores best practices and case studies in aseptic processing, including how to implement and manage PUPSIT. You will learn:
• Integrity Testing – the background on IT itself, why it is important, and how it works
• Filtration setups and single-use technology
• The PUPSIT debate and how PUPSIT can be achieved with current technology, final filling, formulation, filtration
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.emdmillipore.com/remotevisit
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...Merck Life Sciences
View the recording here: https://bit.ly/2M6cTYD
Abstract:
Diafiltration is a critical unit operation in the downstream purification train for nearly all monoclonal antibodies and other therapeutic biomolecules, with a particular application being the final formulation step. It provides a cost-effective, efficient, and robust method for achieving > 3 logs of buffer exchange. As the biomanufacturing industry strives for more efficient and cost-conscious processes and facilities by adapting templates to be more flexible, handle larger batch sizes, require lower plant footprint, and run in an integrated or continuous mode, diafiltration has been one of the last unit operations to change. Updated technologies for chromatography, clarification, and concentration have been developed in recent years, offering significant improvements over their existing batch processing equivalents. However, it has been challenging to develop a similar intensified and continuous technology for diafiltration that exceeds established expectations around unit operation productivity while maintaining a process that is easily implementable and suitable for GMP manufacturing.
Our approach to intensified, continuous diafiltration bases the process design on membrane utilization, as opposed to flux and process time typically used for batch designs. The result is a flexible solution that offers 6-8-fold decrease in membrane area, up to 3-fold reduction in pump passes and a substantial footprint reduction. Buffer usage, extent of buffer exchange, and product yield are equivalent to a traditional constant-volume diafiltration process. The process development approach, system components, and process control rely on well-established methods and technologies, reducing risk during scaleup and manufacturing implementation.
In this webinar, you will learn:
- A new process design for continuous diafiltration and its operational robustness over a 24-hour run
- Benefits of implementing this version of intensified or continuous diafiltration in your process train
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...Merck Life Sciences
What are the major drivers for the new Annex 1? Join us to know more about implications for Filters & Single Use.
In this webinar, you will learn:
• Closed Processing and Single Use Technology implementation
• Points to consider using Single Use Technology
• Sterile Filtration
The Annex 1 “Manufacture of sterile medicinal products” of the EU GMP Guide is currently being revised. A first draft of the revised version was published in 2017 and released for public comment. The second draft as of February 2020 was open for targeted consultation via stakeholder from selected industry organisations. The current Annex 1 draft emphasises Contamination Control Strategy (CCS) multiple times and as a key consideration.
Single-Use Tangential Flow Filtration for Closed ProcessingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b7vD60
Closed processing involves use of physical barriers to separate processing fluid from the external environment. This approach reduces capital expenditures and clean room classification while accelerating time to market. This webinar will present a TFF process run in a closed mode.
Closed processing with single-use technologies is a critical enabler for efficient and robust manufacturing for novel modalities as well as continuous biomanufacturing processing. It can also reduce the dependence on classified clean rooms for traditional modalities. This approach helps to mitigate the risk of contamination by adventitious agents while enhancing operator safety.
In this presentation, we discuss the implementation of closed processing for downstream applications and present the design and performance testing of a single use manufacturing-scale tangential flow filtration system to be able to operate in both functionally and fully closed mode.
In this webinar, you will learn:
• The context of closed processing
• Differences between closed and functionally closed processing
• The drivers for adoption
• Its practical implementation to a TFF step
Aseptic / sterile- “ A state of control attained by using an aseptic work area and performing activities in a manner that precludes microbiological contamination of the exposed sterile product”
This presentation explores bioprocessing filtration best practices, including design and scale up methods. You will learn:
• What is filtration?
• Filter capacity and fouling models
• Filter sizing approaches
• Scale up considerations
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/remotevisit
This presentation covers the manufacture and testing of all sterile drug products, including drugs that are sterilized by filtration or other means and aseptically processed, and drug products that are terminally sterilized. The type of products covered include sterile bulk drugs, ophthalmic drugs, otic dosage forms, small volume parenteral (SVS) products for small molecule and licensed biological
therapeutic drug products, large volume parenteral (LVP) products, and any other drug products required to be sterile or labeled as sterile. Center for Biologics Evaluation and Research (CBER) regulated products and veterinary drug products are excluded from coverage under this program.
The guidance information is tailored to sterile manufacturing operations and should be used in conjunction with the Compliance Program for Drug Manufacturing Inspections (CP 7356.002).
Single-Pass Tangential Flow Filtration (SPTFF) Theory and PracticeMerck Life Sciences
This data-driven presentation explores the theoretical and practical implications of single-pass tangential flow filtration in bioprocessing and will address the following:
• What is single-pass TFF and how does it work?
• How does SPTFF improve process economics?
• How can single-use technology be utilized for speed and safety?
To learn more about this topic or collaborate with our technical experts, schedule an in-person or remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/mlab
Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
Experienced Quality Professional with a demonstrated history of working in the Top leading National pharmaceutical industries (Platinum, Bosch, Getz & Nabiqasim Pharma) of pakistan. Part of WHO & PIC/S Team.
Skilled in various function of Quality Assurance, Quality Management Sysytem,Validation & Qualification as described below.
1-Deviation Management System.
2-Change Control Management System.
3-Corrective & Preventive Action(CAPA).
4-Root Cause Analysis(Investigation).
5-Self Inspection (Level-I), GMP Inspection (Level-II), Internal Audit (Level-III).
6-Quality Risk Management System.
7-Market Complaint (Product Quality Defect).
8-Product Recall (Mock Recall).
9-Product Quality Review(APQR).
10-Management Review.
11-Supplier Qualification
12-ISO (9001,14001,45001 & 17025)
13-Validation Master Plan
14-Process Validation
15-Area & Equipment Qualification
16-Cleaning Validation
17-Calibration & Verification
18-Analytical Method Validation
Batch Manufacturing Record Auditing and Sop writing along with effective training sessions reagrding GMP.GDP.GLP & GSP.
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...Merck Life Sciences
This presentation provides an introduction to tangential flow filtration applications for AAV and lentivirus and will review:
• Basics of tangential flow filtration (TFF)
• TFF AAV and lentivirus process overview
• Operating parameters optimization: flux-controlled microfiltration
• Scale up considerations
To learn more about this topic or collaborate with our technical experts, schedule a remote visit at our M Lab™ Collaboration Centers: www.merckmillipore.com/remotevisit
Bioburden control: Strategies to address bioburden control in downstream proc...Merck Life Sciences
Biotherapeutic manufacturing processes are at greater risk of contamination than classic small molecule processes and therefore require different control strategies. Understanding the source, options for control, and potential impact of bioburden throughout downstream biopharmaceutical processes is beneficial to process developers, production operators and pharmaceutical microbiologists. Process designs that reduce the risks of bioburden contamination will decrease process related failures and the resulting painful, time-consuming investigations.
In this webinar, you will learn:
• Biotherapeutic manufacturing processes are at greater risk of contamination than classic small molecule processes and therefore require different control strategies.
• Understanding the source, options for control, and potential impact of bioburden throughout downstream biopharmaceutical processes is beneficial to process developers, production operators and pharmaceutical microbiologists.
• Process designs that reduce the risks of bioburden contamination will decrease process related failures and the resulting painful, time-consuming investigations.
Register for our webinar here: https://bit.ly/3c4q9rr
The Role of BPOG Extractables Data in the Effective Adoption of Single-Use Sy...Merck Life Sciences
The successful adoption of single-use technologies in a biopharmaceutical process largely relies on confidently selecting the right components for use in the fluid path of a product, within a specific process. An important step in choosing such components requires generating an extractables profile, which can be done by carefully selecting the solvent streams and extraction conditions to model the product and process steps complemented with the right analytical strategy.
In this webinar, you will learn:
● An approach to adopt the BioPhorum Operations Group (BPOG) extractables protocol as a baseline testing strategy.
● How to apply extractables data to a specific process followed by a systematic, risk-based safety assessment approach used for comparing known safety concern thresholds.
● The important stages in the risk assessment process as demonstrated by case studies from typical drug manufacturing processes where single-use components were used.
Discover solutions for all phases of product development for genetox assessment from in silico analysis, screening, mode of action assessment, or GLP regulatory required assays. Our BioReliance® Genetic Toxicology Services director will share specifics and rationale for each assay category.
In this webinar you will:
- Learn the required regulatory assays
- Understand why each assay is used and how to employ different assay designs
- Learn different assays and techniques to screen potential compounds and understand mechanism and mode of action
Presented by Rohan Kulkarni, Ph.D., ERT, Director Toxicology, Study Management on February 9, 2017
Serum-free Media for Therapeutic Cell Manufacturing – Challenges and InnovationsMerck Life Sciences
The need for high quality materials that are animal origin-free and compatible with a limited number of downstream processing steps will increase as cell therapies achieve clinical success. Large scale manufacturing necessitates transition from planar culture to technologies such as stirred tank bioreactors where culture of suspension cells or adherent-dependent cells on microcarriers is enabled.
This webinar will discuss challenges and solutions to the elimination of animal-derived components from cell culture processes, with focus on human mesenchymal stromal/stem cells (hMSCs). Fetal bovine serum in particular is associated with regulatory, supply, and consistency challenges, yet a wide range of performance has been observed between different serum-free media formulations for expansion of hMSCs in planar formats. Moreover, a positive performance in static culture is not necessarily predictive of that under agitated conditions with microcarriers, highlighting ongoing challenges to the generation of a fully chemically-defined and scalable cell culture medium. Through use of pharma-grade basal media manufactured with advanced milling technology and EMPROVE® raw materials, as well as transition to serum-free supplementation and process development activities, the robust expansion of hMSCs across platforms has been achieved.
Presented by Aletta Schnitzler, Senior Scientist on 5/5/16
Considerations for Manufacturing Commercial Antibody Drug Conjugates (ADCs) -...Merck Life Sciences
ADC manufacturing presents a unique set of challenges as compared to the well established practices employed for more traditional biologic products.
The development and commercialization of key intermediates, complex small-molecule APIs and biologic drug substances shouldn’t be such a headache. The uniqueness, versatility, and complexity involved in each project only means you need to make sure you’re well informed when it comes to the dos and don'ts of manufacturing commercial Antibody Drug Conjugates (ADCs). Tune in to hear a CMO perspective for an in-depth understanding on the subject of manufacturing commercial ADCs. Our team will discuss all of the considerations that must be addressed to successfully manufacture ADCs.
In this webinar you will learn:
- Facility Design and Cleaning Validation
- Advantages of Single Use Systems
- Process Control and Regulatory Strategies
Our Life Science business is fully dedicated to supporting small, biotech companies with cutting edge technologies. Besides technical aspects of molecule development and production, fundraising is omnipresent. This webinar will provide insights and perspectives from Merck Ventures, BV, a subsidiary of
Merck KGaA, Darmstadt, Germany.
At Merck Ventures, BV, a subsidiary of Merck KGaA, Darmstadt, Germany, the strategic corporate venture capital arm of Merck KGaA, Darmstadt Germany, we drive innovation and back entrepreneurs through equity investments and hands-on support. We focus on areas that impact the vitality and sustainability of our current and future businesses.
This webinar will provide you with the ABCs of venture capital including:
• How venture capital works
• The role of a corporate venture capital
• How we look at opportunities
Are you involved with planning tech transfer of your drug product? Join this webinar to learn more about the regulations and considerations you need to consider and learnings from a case study.
According to ICH Q10, “The goal of technology transfer activities is to transfer product and process knowledge between development and manufacturing, and within or between manufacturing sites to achieve product realization. This knowledge forms the basis for the manufacturing process, control strategy, process validation approach, and ongoing continual improvement.”
As a result, there is an expectation for transfers to be performed in an organized, methodical manner with appropriate documentation. It is also expected that they happen between one Process Development group to another or to a Pilot Lab, from Process Development lab to clinical or commercial manufacturing, or from Process Development to external clinical manufacturing. Lastly, they may also happen between two company facilities at commercial scale, or between a company and an external contract manufacturing at commercial scale.
This presentation will cover points to consider for successful tech transfers with a focus on cGMP training requirements, and include lesson learned from real cases.
Presented by Guillaume Plane on September 22, 2016
Time is of the Essence: Creating a New Synergy Between Single-Use Adopters an...Merck Life Sciences
Biopharmaceutical companies race to achieve milestones, advance promising molecules, improve productivity and reduce costs. In addition to perfecting the biology, companies must grapple with challenges such as standardization of process technology, supply security and process economics, especially in light of the burgeoning interest and adoption of single-use systems. Efficient implementation of single-use systems is more than incorporating disposable components into the process. It requires a new approach by suppliers of these systems to nimbly and effectively address such challenges.
This session will highlight best practices for creating a new synergy between biopharmaceutical companies and single-use suppliers to strike the right balance of design flexibility, supply predictability and reliable lead times necessary to beat the clock. A case study describing a more efficient and practical “bottoms-up” approach to configuring and delivering single-use assemblies will be presented.
In this webinar, you will learn:
- How to choose single-use assemblies that are best suited for your process
- Risk reduction strategies that incorporate stock or specialized single-use assemblies vs. custom solutions
- Best practices to strike the right balance of design flexibility and supply predictability
An Integrated Approach to Ensure Viral Vector and Gene Therapy Commercial Rea...Merck Life Sciences
Come learn more about our integrated approach to ensure viral vector and gene therapy commercial readiness. We will discuss topics relating to process development for viral vector manufacturing, biosafety testing and commercial readiness.
Significant progress has been made for the use of viral vectors for gene therapy. Promising clinical trial results as well as recent FDA approval for CAR-T cell therapy to treat certain children and young adults with B-cell lymphoblastic leukemia have signaled advancements in the field. This marks a historic action, providing opportunities for new viral vector technologies to transform medicine and the way patients are treated and even cured. The need for process development for viral vector manufacturing to improve yield to meet patient demand, biosafety testing for product characterization, potency and safety and commercial readiness to accelerate therapy to-market are critically important. Here, we emphasis an integrated approach that allows our customers solutions to ensure viral vector and gene therapy commercial readiness to meet the growing market need.
In this webinar, you will learn:
● Process development advances for production scale-up of viral vectors for gene therapy
● Methods specific for viral gene therapy product characterization, purity, potency, safety and release testing
● Commercial readiness through our US and UK Centers of Excellence for viral product manufacturing
Modern BioManufacturing: Single-Use Technologies in Configurable, Prefabricat...Merck Life Sciences
A co-webinar describing a solution to biopharma's challenge of rapidly and rationally expanding capacity by employing single-use technologies, a templated process train, and pre-fabricated mobile/modular cleanrooms.
Biopharmaceutical companies on the verge of investing into manufacturing or facilities expansion face many questions and challenges. Speed, agility, and flexibility are becoming more critical to executing their changing production and distribution strategies. Platform facility designs which integrate the latest process technologies within innovative pre-fabricated cleanrooms are critical for addressing the trending desire to implement 'clonable' modular facilities that can be delivered in a timely fashion across multiple locations. Companies like Merck KGaA, Darmstadt, Germany and G-CON Manufacturing are working together to combine their technologies and develop simple yet robust platform solutions for industry.
As bioprocessing technologies intensify performance, volumetric requirements become less. As such, 2000L single-use bioreactors - or multiple bioreactors of similar or less volumes - now suffice for the production of novel or biosimilar recombinant proteins. Such a shift in the industry enables the development of more mobile, modular facility designs. We will describe the rationale for this collaboration and its result: a turn-key solution that integrates a templated process train with a rapidly-deployable facility platform. By combining the unique advantages found with the G-CON POD construction and the bioprocess technology expertise from within Merck KGaA, Darmstadt, Germany, the goal of creating a cost-effective, pre-fabricated alternative to historical 'stick built' facilities is being achieved. Additionally, the flexibility inherent to our approach provides for a greater configurability that confers more user-specified choice into the selection of options. Simple in concept, this solution is also robust, cost-effective, and conducive to tight timelines for implementation.
In this webinar you will learn:
- Basic options for facilities/capacity expansion
- The value of templated process trains employing single-use equipment
- How modular, prefabricated PODs® outfitted with such single-use bioprocessing equipment represent an attractive, cost-effective strategy for capacity expansion
POD® is a registered trademark of G-CON Manufacturing, Inc.
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsMerck Life Sciences
Learn about existing and emerging methods to accelerate biosafety testing of biologic therapies.
Speed to market for biologic therapeutics is ever more critical. However, the critical safety tests for these molecules, for example screening for adventitious agents such as viral contaminants, can be time consuming as well as challenging and laborious. Join us for this webinar as we explore how rapid methodologies are being used to not only accelerate this process, but also enhance quality by reducing testing complexity. Existing technologies as well as emerging trends will be discussed, along with the implications these may have on the regulatory landscape.
In this webinar you will learn:
● Which existing and emerging technologies are having now, and will have in the future, an impact on biosaftey testing.
● The benefits as well as risks of employing rapid methods for biosafety screening.
● How the regulatory agencies are reacting to rapid testing methods as alternatives to existing methods.
Viral Risk Mitigation Strategies: Key Considerations in the Prevention and De...Merck Life Sciences
Regulatory guidelines have defined industry best practices around adventitious virus contamination and risk mitigation in terms of patient safety.
Today, the industry is taking a closer look at minimizing the business risk associated with viral contamination and is taking a more directed view of risk mitigation. This approach includes virus prevention and detection, in addition to removal.
From cell culture seed train to final fill vial, this presentation will describe:
-Potential risks associated with different areas of biotech processes
-What can be done to minimize adventitious virus risk in those areas.
The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, as well as testing and regulatory considerations.
Delivering More Efficient Therapeutic Protein Expression Systems Through Cell...Merck Life Sciences
Historically cell line performance has been enhanced through media, feed and process optimization, primarily through trying to meet the basic nutritional requirements of the cells so that they can sustain high growth and productivity throughout the production runs.
However, the omics (genomics, transciptomics and metabolomics) era, sequencing of the CHO genome and enhancements in genome editing technologies over the past several years have enabled scientists to take a more direct route in cell line optimization through the modification of specific genes that have direct implications on cell culture performance, protein quality attributes and upstream and downstream manufacturing processes. These targets include but are not limited to genes that may be involved in cell cycle regulation, cellular metabolism, cellular transcription and translation, the secretory pathway and protein glycosylation or other post-translational modifications.
In this webinar we will discuss specific genetic modifications that have been made to CHO cell lines and how these modifications can lead to more efficient expression systems.
Distillation is one of the widely used separation method in most of the chemical process industries. Improper design
/operation & maintenance leads to various troubles like reduced plant capacity, poor quality of separated products,
high energy (utility) consumption, etc.
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...Merck Life Sciences
Protein viscosity is a major challenge in preparing highly concentrated protein formulations suitable for subcutaneous injection. Recently, the Viscosity Reduction Platform (VRP) was introduced and its technical key features and benefits for formulations were discussed. However, highly viscous solutions do not only pose a challenge when administering a drug to a patient, they can also impose technical limitations in the manufacturing process.
This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.
Find more information about the Viscosity Reduction Platform on our website: https://www.sigmaaldrich.com/products/pharma-and-biopharma-manufacturing/formulation/viscosity-reduction-platform
Use of Excipients in Downstream Processing to Improve Protein PurificationMerck Life Sciences
Excipients are used to improve the stability of protein-based therapeutics by protecting the protein against a range of stress conditions such as temperature changes, pH changes, or agitation. Similar stresses are applied to proteins during downstream purification. Shifts in pH during Protein A chromatography, subsequent incubations at low pH for virus inactivation, and changes in conductivity in ion exchange chromatography can lead to aggregation, fragmentation, or other chemical modifications of the therapeutic protein. Given the potential impact on the protein’s structural integrity, there is a need for approaches to reduce the risk presented by the conditions during downstream processing. For example, integration of a solution to prevent aggregation of proteins would be a more efficient strategy than implementing steps to remove multimeric forms.
This white paper highlights the results from a recent paper by Stange et. al., in which protein stabilizing excipients such as polyols, sugars, and polyethylene glycol (PEG4000) were used as buffer system additives. Effect of the excipients on elution patterns, stabilization of the monomer antibody, host-cell protein removal, virus inactivation rates and binding capacity of cation exchange chromatography were explored.
Exploring the protein stabilizing capability of surfactants against agitation...Merck Life Sciences
Agitation of therapeutic protein solutions during manufacturing, shipping and handling is one of the major initiators for protein aggregation and particle formation during the life history of a protein drug. Adsorption of protein molecules to liquid-air interfaces leads to the formation of highly concentrated protein surface films. The rupture of these protein films due to various mechanical processes can then result in the appearance of protein aggregates and particles in the bulk solution phase.
One technique to stabilize proteins against stress induced by liquid-air interfaces is the use of non-ionic surfactants. About 91% of antibody formulations commercially available in 2021 contained a surfactant. Polysorbate 20 and 80, composed of a hydrophilic polyoxyethylene sorbitan and hydrophobic fatty acid esters, made up the largest part being employed in 87% of said formulations.
Despite their frequent use in parenteral drug products, concerns have been raised for decades about the application of polysorbates as surfactants in biopharmaceutical formulations. Autoxidation of polysorbate, caused by residual peroxides in polysorbates, can damage the proteins and can further drive the oxidative degradation of polysorbate. Chemical and enzymatic hydrolysis of polysorbate may lead to the formation of free fatty acid particles, which may become visible; and both mechanisms eventually lead to the reduction in polysorbate concentration. Therefore, the purpose of the current study was to compare various molecules for their capabilities to reduced agitation-induced protein aggregation and particle formation; and furthermore, investigate their underlying protein stabilizing mechanisms.
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...Merck Life Sciences
Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous injection.
This whitepaper examines how combining an amino acid with a second viscosity-reducing excipient circumvents adverse effects on protein stability and improves viscosity-reducing capacity.
To find more information about the Viscosity Reduction Platform, please visit our website: https://sigmaaldrich.com/products/pharma-and-biopharma-manufacturing/formulation/viscosity-reduction-platform
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
Watch the presentation of this webinar: https://bit.ly/3Pjpjvr
Highlights of this webinar:
- Surface plasmon resonance as a powerful tool for biologic characterization including mAbs and ADCs.
- SPR allows rapid binding analysis in real time without using labels for SARS-CoV-2 receptor binding domain mutations.
- Kinetic data is indicative of possible neutralizing activity allowed assessment of neutralizing ability of therapeutic monoclonal antibodies.
- The application can provide preliminarily efficacy information and facilitated mAbs/ACDs candidate selection process
Detailed description:
Characterization of therapeutic monoclonal antibodies (mAbs) or Antibody drug conjugates (ADCs) is challenging due to their ability to bind to a variety of proteins via their Fc and Fab domains, giving rise to diverse biological functions associated with each domain. The Fc domain of mAbs interacts with Fc receptors with varying affinities, which can influence biological processes such as Complement-dependent cytotoxicity (CDC) and Antibody-dependent cellular cytotoxicity (ADCC), transcytosis, phagocytosis, and/or serum half-life.
An important characteristic of an antibody is its Fc effector function. Antibodies can be engineered to obtain desired binding of the Fc region to Fc receptors expressed on effector cells. Hence, it is crucial to evaluate the binding interaction of mAbs/ADC with Fc receptors in the early phase of drug development to understand the potential biological activity of the product in vivo.
Surface Plasmon Resonance (SPR) is a powerful technique to establish binding kinetics in real-time, label free, and high sensitivity with low sample consumption. Along with target antigen binding, it is crucial to evaluate the binding interaction of antibodies and ADCs with Fc receptors. Our SPR case studies investigated the impact on binding kinetics of ADCs with different linkers and the binding interactions of SARS-CoV-2 spike protein variants and evaluated the neutralizing ability of therapeutic mAbs. SPR characterisation can be facilitated in all stages of the product life cycle to ensure the quality and safety of mAbs and ADCs.
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...Merck Life Sciences
Regulatory expectation does require patient safety evaluations with supporting data for manufacturing components that directly come into contact with drug manufacturing process streams. Readily available extractables data can help manufacturers using singleuse technology to accelerate product qualifications, risk assessments and process optimization
This white paper guides you on how to save time and resources with supplier-provided single-use system extractables data and gives you an overview about the overall strategy for Extractables & Leachables. At the end you will find a case study.
Find more information about filters and single-use components on our website: https://www.sigmaaldrich.com/DE/en/services/product-services/emprove-program/emprove-filter-and-single-use-component-portfolio
Watch the recording of this presentation here: https://bit.ly/3zTOpe4
Detailed description:
SARS-CoV-2 showed us that technology supports us during our inspection activity even if on-site visits are not possible. Travel restrictions of various kinds will remain a risk in the future. The use of new technologies has shown that inspections and audits can be carried out despite these restrictions. We will focus on what possibilities the new technologies offer and take a look at the future of inspections and audits.
In this webinar, you will learn:
• Regulatory overview of remote audits
• The technologies needed to support the audit process
• What types of inspections are possible with the use of these technologies
• How audits may look in the future
Presented by:
Daniel Buescher, Product Manager - Digital Solutions
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Merck Life Sciences
Watch the recording of this presentation here: https://bit.ly/3SqOsoP
Novel therapies, including cell and gene therapies, continue to be central to innovation in healthcare and represent the fastest growing area of therapeutic medicine. As a consequence, the number of gene therapies undergoing clinical trials has increased significantly in the last five years.
Manufacturing processes for these novel therapeutics are very complex with a high risk of contamination. Regulatory agencies world-wide have responded by issuing guidance to outline their expectations for development and manufacture of cell and gene therapies. Currently, regulatory guidance is not harmonized globally and can often lead to confusion within industry and increased risk of non-compliance.
In this webinar, we'll answer:
• Which regulatory guidelines do you need to comply for your INDs?
• When do you start implementing GMPs and validated assays?
• How do you get your QC testing strategy ‘right the first time’?
• How do you ensure testing is not your rate limiting step for the IND submission?
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Dr. Alison Armstrong, Sr. Director, Technical and Scientific Solutions
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3RijkHC
Detailed description:
Imagine you’ve just completed a manufacturing run for your viral vector. Identity testing is performed to confirm the vector sequence. But when the results come back the data reveals unexpected sequence variants! With an appropriate risk mitigation testing strategy, this situation can be prevented.
The situation described above is not hypothetical, and happens more that you think, costing valuable time and resources.
Investigatory testing has shown that sequence variants present in starting materials (e.g. plasmids) are likely to make their way to the final product. Adequate identification of low-level variants with an appropriately sensitive method is critical in ensuring the quality of the final product. A risk-based testing strategy, in the context of identity, for viral vector manufacturing will be presented, focusing on key testing points. NGS assays for identity and variant detection will be highlighted due to their extremely sensitive nature compared to traditional approaches.
In this webinar, we'll explore:
• Regulatory requirements for identity testing
• NGS applications for identity testing as compared to traditional methods
• A case study on the impact of not establishing a proper risk-based testing strategy
Presented by: Bradley Hasson, Director of Lab Operations for NGS Services
Latest advancements of melt based 3D printing technologies for oral drug deli...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3A2WcH4
The application of polymer excipients in 3D printing manufacturing is usually limited due to the concerns of filament strength, high processing temperature and large scale manufacturing.
Latest technology developments are targeting a direct melt deposition to simplify the process and enable a constant and efficient process. Two different processing approaches will be presented:
The advanced melt drop deposition, where individual three dimensional geometries can be created by depostition of polymer droplets and the MED® 3D printing technology which allows by precise layer-by-layer deposition to produce objects with well-designed geometric structures.
In this webinar, you will learn:
• Latest advancements of melt based 3D printing approaches
• Application examples for the individual technologies
• Deep dive in the MED® 3D printing technology to design dedicated drug release profiles
Presented by:
Dr. Thomas Kipping, Head of Drug Carriers
Dr. Xianghao Zuo, Deputy Director of R&D, Triastek
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3NDNIKe
Automated, fit-for-purpose tools are essential in CAR-T processing to support sustainable manufacturing of clinical and market-approved cell therapy products. This webinar will discuss how the ekko™ Acoustic Cell Processing System uses acoustic technology as a touchless approach to manipulate cells, enabling a modular tool across the CAR-T manufacturing workflow. Typical performance of templated ekko™ System processes for DMSO washout of leukapheresis material, low volume and high cell concentrate for electroporation preparation, and harvest of expanded T cells will be reviewed.
This webinar will also give an early glimpse at the ekko™ Select System for unmatched T cell selection.
In this webinar, you will:
• Uncover how the ekko™ System supports the broad industrialization of cell therapy, with particular focus on how to achieve low volume, high concentrate cell product for critical transduction and transfection steps
• Discover how ekko™ System for wash and concentrate processes throughout the cell therapy workflow achieve high cell recovery, viability, and effective residual removal
• Preview to ekko™ Select, our cell therapy selection platform, to achieve unmatched ease-of-use with direct processing from leukopaks reducing the need for preparation steps
Presented by:
Benjamin Ross-Johnsrud, Acoustic Technology Expert
Robert Scott, Mechanical Engineer III
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3t7X9tg
How does the ICH Q5A revision impact viral safety strategies for biologics?
Biologics continue to grow at a fast pace. Manufactured using cell lines of human or animal origin, these are at risk of viral contamination making safety strategies critical. A comprehensive risk mitigation strategy using multiple orthogonal measures is a regulatory expectation. ICH Q5A, the globally-harmonized guideline outlines the expectations. ICH Q5A is currently being revised to address recent scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and alternate detection technologies. We’ll discuss the expected changes and potential impact on viral safety strategies with case studies and examples.
In this webinar, you will learn about:
• The Importance of virus testing in biologics products
• Regulatory landscape, expectations for the Q5A revision
• What's new and changing
• Examples of alternate testing schedules, impact on viral clearance
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Alison Armstrong, PhD, Sr. Director, Technical and Scientific Solutions
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3adaxWh
When implementing new automation systems, organizations must consider things like deployment time, user adoption, and costs.
They must also consider the cost of doing nothing – that is, what competitive advantage is lost in standing still? What time and quality is lost in repetitive, manual tasks rather than an automated, digital workflow? What operational efficiencies are lost?
In this webinar we examine how a product, process, and system agnostic automation platform can be deployed faster than traditional system specific software while bringing greater operational efficiencies (in many cases over 30% improvement).
To remain competitive in the market, biopharma manufacturers must adopt automation and digital technologies, but most plants still have island of automation consisting of independently functioning, standalone unit operations. This results in operational inefficiency, regulatory concerns, and a poor understanding of the process and product life cycle.
Taking the first, right step must include considering risks, costs, timelines, and technology alternatives. Traditional automation approaches tied to specific systems, processes, and products are, by their nature, limited; while an agnostic platform will address current biomanufacturing business challenges and ensure future readiness. With the right platform, a phased automation implementation can yield operational efficiency gains of up to 30% and improved product quality and regulatory compliance.
In this webinar, let's explore:
• Challenges of automation and digital technology adoption
• What a product, process, and system agnostic platform entails
• Applications and benefits of a process orchestration platform
• Ensuring future readiness with process orchestration
Presented by:
Braj Nandan Thakur, Global Product Manager - Automation
Insights from a Global Collaboration Accelerating Vaccine Development with an...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3Nbb5ug
Get insights and best practices from a multinational team establishing a platform for vaccine production. See how a long-term collaboration on a bench-scale process used to produce a Virus Like Particle (VLP) vaccine for SARS-CoV-2 was successfully converted to a robust GMP-compatible, scalable process.
The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with Technovax and Innovative Biotech in which a scalable VLP vaccine platform was optimized for use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine.
In this webinar, you will learn:
• About building a priceless collaborative network with integrated solutions
• Virus-Like Particle Vaccines
• Process Development Overview and Challenges
• Pre-clinical Results and Next Steps
Presented by:
Jose M. Galarza, PhD,
President and Founder of TechnoVax
Naomi Baer,
Business development consultant, Emerging Biotech, BioProcess division
Youssef Gaabouri, Eng. ,
Associate Director, Head of Sales Middle East & Africa, BioProcess division
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3vQf0qv
In the single-use bioprocess industry, X-ray irradiation warrants consideration as an alternate sterilization technology. Using a risk-based qualification testing strategy is important when evaluating and implementing equivalent ionizing irradiation sterilization methods.
The urgent need for life-saving therapies as a result of the global pandemic has reinforced the criticality of flexibility in pharmaceutical manufacturing, including sterilization. The single-use bioprocess industry traditionally has employed gamma irradiation sterilization. X-ray irradiation is being considered as an additional sterilization technology for business and supply continuity. We will share a risk-based qualification testing strategy including Extractables and data generated to support comparability of gamma irradiation and X-ray irradiation as equivalent ionizing irradiation sterilization methods.
In this webinar, you will learn about:
• The comparison of gamma and X-ray irradiation sterilization
• A risk-based qualification test strategy
• Data evaluation of gamma versus X-ray sterilized single-use components
Presented by:
Monica Cardona,
Global Senior Program Manager
Paul Killian, Ph.D.,
R&D Director, Analytical Technologies
Rapid replication competent adenovirus (rRCA) detection: Accelerate your lot ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3MJ4u9V
Testing for presence of replication competent adenovirus (RCA) is a key component to ensure patient safety and a requirement for all biologicals manufactured using adenoviral vectors. For many adenoviral-based products, the RCA assay is a rate-limiting assay for lot release.
Join this webinar to learn about a rapid RCA detection assay currently in development, which combines a 7-day culture assay with a highly sensitive molecular endpoint specific for RCA. The method can detect presence of as little as 1 RCA in adenoviral vector material at an approximate concentration of 5x107 - 2x108 vector particles (VP)/mL, making it a suitable method to meet regulatory requirements while accelerating your lot release timelines.
In this webinar, you will learn about:
• Regulatory framework for adenoviral vector products
• Considerations for lot release testing of adenoviral-based therapies
• Advantages of a rapid method for RCA testing on production lot material
Presented by:
Axel Fun, Ph.D.,
Principal Scientist
Alberto Santana, MBA,
Product Manager, Biologics Biosafety Testing
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3vQyN7K
Bitter medicines are an important issue, especially for pediatric applications. As several APIs have bitter tasting components, high intensity sweeteners for taste optimization are of great interest. Join our webinar to discover our new sweetener toolbox enabling safe and stable formulations.
Mask bitter aftertaste for a sweeter pill to swallow! Patients’ compliance and the therapeutic benefit are supported by a pleasant taste of pharmaceutical formulations. With the high intensity sweeteners Neotame and Sucralose, you have efficient tools at hand which are superior to other sweeteners in many aspects:
• excellent sugar-like taste profile
• outstanding sweetness factors
• use effectiveness
• enhanced stability
We will present our new toolbox of two high performance sweeteners and focus on aspects of stability, safety, the application in various dosage forms, and market perception.
In this webinar, you will learn:
• How to optimize the patients' taste experience of your pharmaceuticals
• How sweeteners can be differentiated by their sensory profiles and features
• How our new product offering Neotame can be effectively used in your targeted formulations
Presented by:
Almut von der Brelie,
Senior Manager Strategic Marketing
Excipients for Solid Applications
The Developability Classification System (DCS): Enabling an Optimized Approac...Merck Life Sciences
This whitepaper by Dr. Daniel Joseph Price outlines how poorly soluble drug formulations can be designed using the developability classification system (DCS).
The DCS identifies the root cause of low solubility and enables lean, cost-effective and effective formulations to be developed.
#solubility #pharmaceuticalmanufacturing #oralsoliddosage #drugdevelopment
In this webinar, you will learn about:
The advantages of using advanced intermediates to develop ADC therapies
How to increase ADC solubility and efficiency
Fast, small-scale ADC library generation
Seamless supply chain with reduced complexity and regulatory support
The ADCore product line offers versatile intermediates that simplify the synthesis of common ADC payloads (dolastatins, maytansinoids, and PBDs) by greatly reducing the number of synthetic steps. This translates to savings in development and manufacturing costs and shorter timelines to the clinic. To address the poor solubility of many ADC payloads, ChetoSensar™ was developed to significantly increase the hydrophilicity of the drug linker, which has been shown to also substantially increase the efficacy of ADCs and broaden the therapeutic window.
Lastly, the ADC Express™ service leverages conjugation chemistry and analytical expertise to help design and quickly synthesize sets of potential ADC therapies suitable for screening to simplify candidate selection and get ADC therapies to market faster.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Integrity Test Troubleshooting – Beyond Rewet and Retest
1. NOT FOR U.S. AND CANADA AUDIENCE
Randy Wilkins
Principal Technical Consultant
2. 2
• “Retesting is just a routine part of the process”
- The best option for troubleshooting is to not have to do it in
the first place
- Webinar: Filter Integrity Testing Best Practices
http://bit.ly/2jEKlEm
• “Filters always fail because they are not wet properly”
- Poor wetting is a reason, but far from the only reason
- Ignoring other potential failure modes result in lost time,
product and frustration
Integrity Testing Myths
3. 3
• “Retesting is just a routine part of the process”
- The best option for troubleshooting is to not have to do it in
the first place
- Webinar: Filter Integrity Testing Best Practices
http://bit.ly/2jEKlEm
• “Filters always fail because they are not wet properly”
- Poor wetting is a reason, but far from the only reason
- Ignoring other potential failure modes result in lost time,
product and frustration
• “You are only allowed to re-test the filter twice”
- You can’t simply retest until you get the answer you want
- Why impose a limit?
- If the reason for a failed/invalid test is clear and
documented, why limit the option for a re-test?
Integrity Testing Myths
4. 4
Demystifying Integrity Test Filters
Understanding the possible causes of IT failures
Being able to apply a logical step-by-step re-test procedure to distinguish between a
false failure and a real failure
Developing internal trouble shooting SOP to establish the root cause of IT failures
After today’s session you will be able to improve your internal IT process by:
5. 5
Integrity Test Review
Integrity tests are based on capillary forces that hold liquid in the pores of wet membranes. Liquid in the
pores of the membrane are a barrier to bulk gas flow. The smaller the pores, the stronger the capillary
forces.
4 . k . . cos
BP = -----------------
d
• k = shape correction factor
• = surface tension
• = contact angle
• d = pore diameter
Bubble Point Test
K . (P1 - P2) . A .
Diffusion = --------------------
L
K = Diffusivity / Solubility coefficient
P1, P2 = Pressure difference
across the system
= Membrane porosity
L = Effective path length
A = Membrane area
Diffusion Test
5
6. Integrity Test Review – Diffusion
Liquid is held in the pores of a fully wetted membrane filter by
capillary forces
A pressure differential will give a gas concentration gradient across
the filter.
Results in diffusive gas flow from upstream to downstream.
Wet membrane
Apply pressure
from validated
specification
Hold pressure
6
7. 7
Integrity Test Review - Diffusion
Gas flow rate within specification indicates flow is solely
from diffusion, which indicates the absence of defects or
over sized pores.
Out of specification
GasFlow
Within
specification
Pressure
Bad filter
Good
filter
Measure the
gas flow rate
8. Integrity Test Review – Bubble Point
8
Out of
specification
Within
specification
GasFlow
Pressure
Durapore®
CVGL:
50psid
Good
filter
Bad filter
Wet Membrane
Water is held in the pores by
capillary force
Gradually raise
pressure
Sufficient pressure will
overcome capillary forces and
push liquid from the filter
Determine pressure
were onset of bulk
flow is observed
The smaller the pores, the
higher the bubble point
pressure
9. Integrity Test Review – Automated Testing
9
All else being constant, the change in pressure
can be used to determine the gas flow rate
1
During integrity testing gas molecules flow
through the filter and leave the system
2
Fewer gas molecules upstream result in lower
pressure
3
Upstream Pressurized
Compressed gas
Gas flow
10. Potential Results – General Categories
• What are potential results?
10-inch Durapore® filter specifications
Bubble point ≥50 psi
Diffusion ≤ 13.3 cc/min at 40 psi
GasFlow
Pressure
Diffusion spec
Bubble Point spec.
10
11. Potential Results – General Categories
GasFlow
Pressure
Diffusion spec
Bubble Point spec.
PASS
• What are potential results?
10-inch Durapore® filter specifications
Bubble point ≥50 psi
Diffusion ≤ 13.3 cc/min at 40 psi
Example 1 - PASS
BP = 55 psi
Diffusion = 10 cc/min
11
12. Potential Results – General Categories
• What are potential results?
10-inch Durapore® filter specifications
Bubble point ≥50 psi
Diffusion ≤ 13.3 cc/min at 40 psi
Example 1 - PASS
BP = 55 psi
Diffusion = 10 cc/min
Example 2 – Marginal Failure
BP = 48 psi
Diffusion = 20 cc/min
GasFlow
Pressure
Diffusion spec
Bubble Point spec.
PASS
Marginal failure
12
13. Potential Results – General Categories
• What are potential results?
10-inch Durapore® filter specifications
Bubble point ≥50 psi
Diffusion ≤ 13.3 cc/min at 40 psi
Example 1 - PASS
BP = 55 psi
Diffusion = 10 cc/min
Example 2 – Marginal Failure
BP = 48 psi
Diffusion = 20 cc/min
Example 3 - Gross Failure
BP < 5psi
GasFlow
Pressure
Diffusion spec
Bubble Point spec
PASS
Marginal failureGross failure
13
14. Potential Results – General Categories
• What are potential results?
10-inch Durapore® filter specifications
Bubble point ≥50 psi
Diffusion ≤ 13.3 cc/min at 40 psi
Example 1 - PASS
BP = 55 psi
Diffusion = 10 cc/min
Example 2 – Marginal Failure
BP = 48 psi
Diffusion = 20 cc/min
Example 3 - Gross Failure
BP < 5psi
Example 4 - Invalid Test
BP > 75 psi
Diffusion = 0 cc/min
GasFlow
Pressure
Diffusion spec
Bubble Point spec.
PASS
Marginal failureGross failure
Invalid
14
15. A Good Troubleshooting SOP is Essential
A well written, properly executed
troubleshooting SOP should answer two
questions:
1. Is the filter integral or not?
2. Why did the test fail in the first place?
15
16. SOP Development – What can go wrong?
Flow and Pressure Wetting Limits
0
10
20
30
40
50
60
0 0.2 0.4 0.6 0.8 1
Flow Rate (lpm/ft^2)
Pressure(psi)
INTEGRITY TEST PASS ZONE
INTEGRITY TEST
FALSE FAILURE ZONE
Recommended
Wetting
Conditions
16
1. Poor wetting
17. SOP Development – What can go wrong?
17
1.
2.
Poor wetting
Wrong test program
18. SOP Development – What can go wrong?
18
1.
2.
3.
Poor wetting
Wrong test program
Wrong filter used
19. SOP Development – What can go wrong?
19
1.
2.
3.
4.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
20. SOP Development – What can go wrong?
20
1.
2.
3.
4.
5.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
21. SOP Development – What can go wrong?
21
1.
2.
3.
4.
5.
6.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
4 . k . . cos
BP = -------------------------
d
• k = shape correction factor
• = surface tension
• = contact angle
• d = pore diameter
Bubble Point Test
22. SOP Development – What can go wrong?
22
1.
2.
3.
4.
5.
6.
7.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Wrong test gas
K . (P1 - P2) . A .
Diffusion = ---------------------
L
K = Diffusivity / Solubility coefficient
P1, P2 = Pressure difference
across the system
= Membrane porosity
L = Effective path length
A = Membrane area
Diffusion Test
23. SOP Development – What can go wrong?
23
z
1.
2.
3.
4.
5.
6.
7.
8.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
24. SOP Development – What can go wrong?
24
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
25. Stable Temperature Environment
Manufacturers specifications are typically established at ambient
temperature (~23°C)
If operating outside of ambient temperature, a ratio should be
established during validation and applied to test specification
- e.g., Cold room operation or heat jacketed housing
Effect of Tem perature on Diffusional Flow rate
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
5 10 15 20 25 30 35 40 45 50 55 60 65 70
Tem perature (C)
CorrectionFactor(Relative
to23C)
There is no significant impact on diffusive flow or BP
over normal ambient temperature range
1
2
25
26. Stable Temperature Environment
Within
Specification
Out of
Specification
AirFlow
ml/min
Time min
Test has to be repeated per retest SOP after
establishing stable test conditions
Apparent Gas Flow
Trained operator can identify the temperature effect by
reviewing the flow curve
Common reasons for temperature changes
Inadequate stabilization after steaming or wetting
with hot WFI
Environmental changes during testing near
autoclave, HVAC outlets, cold room door, near a
window, etc.
When using Automatic Testers, temperature changes
during a test leads to additional upstream pressure
gain or loss – Test Error
Idea Gas Law – PV=nRT
As Temperature increases, Pressure increases
As Temperature decreases, Pressure decreases
Even a change of 1 C DURING the test can lead
to false failure because the pressure change
WILL NOT be solely due to gas flow
26
Flow at
unstable temp
False failure
Flow at stable
temp
27. SOP Development – What can go wrong?
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
27
Common causes for surface tension
suppression:
Residual Product: Develop product based on
integrity test specification and post-use flush
procedure
Application Note
AN1505EN00
28. SOP Development – What can go wrong?
28
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
Common causes for surface tension
suppression:
• Contaminants: New silicone tubing, residual
cleaning agent, etc.
- Identify and eliminate
Freon residue - silicone rubber Millidisk minus body oil
Silicone oil
100020003000
cm-¹
29. SOP Development – What can go wrong?
29
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
Common causes for surface tension
suppression:
• Contaminants: New silicone tubing, residual
cleaning agent, etc.
- Identify and eliminate
Impact of tubing material on the failure of product-specific bubble points of
sterilizing grade-filters Meyer and Vargas, PDA Journal of Parenteral
Science, Vol 60 n°4 2006
30. SOP Development – What can go wrong?
30
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
11. Damaged O-rings
31. SOP Development – What can go wrong?
31
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
11.
12.
Damaged O-rings
Instrument calibration
32. SOP Development – What can go wrong?
32
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
11.
12.
13.
Damaged O-rings
Instrument calibration
Air lock
33. SOP Development – What can go wrong?
33
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
11.
12.
13.
Damaged O-rings
Instrument calibration
Air lock
NOTE: This is not an exhaustive list.
Consider developing a site-specific list by
conducting a brainstorming session with the
people routinely performing the integrity
test.
34. SOP Development – What can go wrong?
34
Pass
Fail
Initial Test
Wet at 1 LPM/0.1 m2 filter area
35. SOP Development
35
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
11.
12.
13.
Damaged O-rings
Instrument calibration
Air lock
Evaluate test results
Verify system set-up and test
parameters
37. Troubleshooting Flow Chart Development
37
Pass
Set up or
Execution
problem
identified
and
corrected
Fail
Initial Test
Wet at 1 LPM/0.1 m2 filter
area
Check test
set-up and
execution
Test set-up
and
execution
verified
correct
38. SOP Development
38
z
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
Poor wetting
Wrong test program
Wrong filter used
Improper seals
Damaged filter
Wrong wetting fluid
Leaks (housing, tubing, integrity tester)
Wrong test gas
Temperature change
Surface tension suppression
11.
12.
13.
Damaged O-rings
Instrument calibration
Air lock
Remaining potential
failure modes require
re-test.
39. Rewet Options
Wetting Option Ease of Implementation Failure Modes Addressed Failure Modes Not Addressed
Longer Time Easy
Poor wetting, non-adsorbed
surface active residuals
Damage, Air Lock, adsorbed
surface active contaminants
Warm Water Flush Easy if facilities are available
Poor wetting, non-adsorbed
water soluble surface active
residuals
Damage, Air lock, adsorbed
surface active residuals
Higher Flow Rate
Easy depending on system
capabilities
Poor wetting, non-adsorbed
surface active residuals
Damage, Air Lock, adsorbed
surface active contaminants
Higher System Pressure Easy
Poor Wetting, non-adsorbed
surface active residuals,
Damage, Air lock, adsorbed
surface active residuals
Alcohol
Complex when alcohol
contamination in the process is a
risk
Poor wetting, non-adsorbed
surface active residuals,
adsorbed surface active
residuals,
Damage, severe air lock
39
40. Pressure Wetting
Standard Wetting
inlet
0
outlet
2
For 0.22 m Durapore® filter devices at 1 lpm/0.1 m2
Inlet pressure = 2 psi/0.14 bar
Outlet pressure = 0 psi/0 bar
p = 2 psi/0.14 bar
High Pressure Wetting
inlet
38
outlet
40
High Pressure Wetting at 1 lpm/0.1 m2
Inlet pressure = 40 psi/2.7 bar
Outlet pressure = 38 psi/2.6 bar
p = 2 psi/0.14 bar
40
41. Rewet Options
Wetting Option Ease of Implementation Failure Modes Addressed Failure Modes Not Addressed
Longer Time Easy
Poor wetting, non-adsorbed
surface active residuals
Damage, Air Lock, adsorbed
surface active contaminants
Warm Water Flush Easy if facilities are available
Poor wetting, non-adsorbed
water soluble surface active
residuals
Damage, Air lock, adsorbed
surface active residuals
Higher Flow Rate
Easy depending on system
capabilities
Poor wetting, non-adsorbed
surface active residuals
Damage, Air Lock, adsorbed
surface active contaminants
Higher System Pressure Easy
Poor Wetting, non-adsorbed
surface active residuals,
Damage, Air lock, adsorbed
surface active residuals
Alcohol
Complex when alcohol
contamination in the process is a
risk
Poor wetting, non-adsorbed
surface active residuals,
adsorbed surface active
residuals,
Damage, severe air lock
41
42. First Retest – High Pressure Wet
inlet
38
outlet
40
42
Pass
Consider poor wetting
as cause of initial test
failure
Fail
First Re-test
Wet at 1 LPM/0.1 m2 filter area with
back pressure
43. Second Retest – Alcohol Wet
43
Pass
Consider presence of
surface active
compounds as the
cause of initial test
failure
Fail
Second Re-test
Wet and test with 70/30 IPA
43
44. Third Retest – Dry and Re-wet with water
4444
Pass
Initial failures likely due
to air lock
Fail
Dry with dynamic air flow or
oven drying at 80 C for 8 hrs
Wet and test with water
Contact filter vendor for
confirmation and defect analysis
45. Summary
• When failing integrity test results occur,
consider all the potential failure causes
- Many are common, some may be site
specific
• Develop a troubleshooting flowchart based
on understanding of failure modes and
remedies
• Conclusions about failure modes may not
be definitive
- A logical approach will yield the best
assessment of failure mode
- Best assessment will yield justification for
re-tests and direction for corrective
actions
45